Department of Pathology, Yonsei University College of Medicine, Severance Hospital, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.
Breast Cancer Res Treat. 2018 Jul;170(1):15-25. doi: 10.1007/s10549-018-4722-1. Epub 2018 Feb 21.
We aimed to evaluate macrophage infiltration and to identify the status of crown-like structures (CLSs) in mammary adipose tissue of human breast tissue in cases with and without breast cancer.
Breast adipose tissue was obtained from reduction mammoplasty (N = 56, Group 1), non-neoplastic breast tissue of breast cancer patients (N = 84, Group 2), and breast cancer with adipose stroma (N = 140, Group 3). Immunohistochemical staining of CD68 and CD163 was performed, and the infiltrating macrophages and CLSs within breast adipose tissue were evaluated.
Group 3 had the largest number of CD68-positive (CD68) and CD163-positive (CD163) macrophages and CLSs within adipose tissue (P < 0.001). Among Group 3, cases with high levels of CD68 and CD163 macrophages commonly had a higher histologic grade (P = 0.016 and P = 0.045), and cases with CD163 CLSs were correlated with old age (P = 0.042), estrogen receptor negativity (P = 0.013), human epidermal growth factor receptor-2 positivity (P = 0.043), and non-luminal A type (P = 0.039). Upon univariate analysis, high levels of CD163 macrophages were associated with shorter disease-free survival in node-negative breast cancer patients (P = 0.033), and CD68 CLSs were associated with shorter overall survival in node-positive breast cancer patients (P = 0.015).
CD68 and/or CD163 tumor-associated macrophage infiltration as well as CLSs are present in adipose tissue nearby the breast cancer lesion, and are associated with various clinicopathologic parameters of breast cancer.
本研究旨在评估乳腺癌患者乳腺脂肪组织中巨噬细胞浸润的情况,并确定冠状结构(CLS)的状态。
本研究从乳房缩小成形术(N=56,第 1 组)、乳腺癌患者非肿瘤性乳腺组织(N=84,第 2 组)和乳腺癌伴脂肪基质(N=140,第 3 组)中获取乳腺脂肪组织。进行 CD68 和 CD163 的免疫组织化学染色,并评估乳腺脂肪组织内浸润的巨噬细胞和 CLS。
第 3 组脂肪组织中 CD68 阳性(CD68)和 CD163 阳性(CD163)巨噬细胞和 CLS 的数量最多(P<0.001)。在第 3 组中,CD68 和 CD163 巨噬细胞水平较高的病例通常具有较高的组织学分级(P=0.016 和 P=0.045),且 CD163 CLS 与高龄(P=0.042)、雌激素受体阴性(P=0.013)、人类表皮生长因子受体-2 阳性(P=0.043)和非腔 A 型(P=0.039)相关。单因素分析显示,CD163 巨噬细胞水平较高与淋巴结阴性乳腺癌患者无病生存率缩短相关(P=0.033),而 CD68 CLS 与淋巴结阳性乳腺癌患者总生存率缩短相关(P=0.015)。
乳腺癌病灶附近的脂肪组织中存在 CD68 和/或 CD163 肿瘤相关巨噬细胞浸润和 CLS,并且与乳腺癌的各种临床病理参数相关。